James R Goodhand

22PUBLICATIONS
78CO-AUTHORS
Nanotoxicology, health and safetyInnate immunityMolecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jun 23, 2025
Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.

Christopher Roberts, Jaime Peters, Aleksejs Sazonvos

|Oct 06, 2023
Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.

Bram Verstockt, Valerie Pivorunas, Naim Al Mahi

|Aug 08, 2023
Whole Blood DNA Methylation Changes Are Associated with Anti-TNF Drug Concentration in Patients with Crohn's Disease.

Simeng Lin, Eilis Hannon, Mark Reppell

|Jun 02, 2023
Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Naïve Patients With Active Luminal Crohn's Disease.

Neil Chanchlani, Simeng Lin, Rebecca Smith

|Aug 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.

Neil Chanchlani, Simeng Lin, Marcus K Auth

|Jul 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.

Nicholas A Kennedy, Malik Janjua, Neil Chanchlani

Pageof 4

Frequent Collaborators

22 joint publications

Tariq Ahmad

19 joint publications

Nick Kennedy

16 joint publications

Neil Chanchlani

15 joint publications

Simeng Lin